The leading allosteric drug discovery and development company which is named as the Addex Therapeutics (SIX: ADXN) has announced today that the members of its management team would take part as follows: Chairman, Tim Dyer, CMO, Roger Mills and the Head of Drug Discovery Biology, Robert Lutjens, on JP 38. Westin St. Francis Hotel in San Francisco, USA: Morgan Healthcare meeting, 13-16 January 2020. Annual J.P The Morgan Healthcare Conference will host about 10,000 industry leaders, growing fast growth firms, innovative technology developers and the investment community participants at the biggest and the most insightful investment symposium in the sector.
Addex Therapeutics is a new class of orally active small molecule drugs known as allosteric modulators for the neurological disorders and is a pharmaceutical company in the clinical stage. Allosteric modulators provide some potential advantages over the non-allosteric traditional molecules and can provide an optimized clinical solution for low, mostly the biological conventional orthosteric drugs. The Addex’s allosteric drug discovery modulator network focuses on the receptors and the other proteins known as the important to therapeutic action. Addex’s principal drug candidate dipraglurant, a staggered 2a POC in the Levodopa-induced dyskinesia (PD-LID) disorder, is effectively established and is prepared to enter the approval tests for PD-LID. PD-LID is currently being submitted. At the same period, the preclinical experiments examine the medicinal use of dipraglurant in the dystonia. In cooperation with the Janssen Pharmaceuticals, Inc. for the treatment of epilepathy Addex’s second clinical programed, ADX71149 (mGlu2 positive allosteric modulator or PAM). In fact, the indivior PLC was approved for the addiction treatment under Addex’s GABAB PAM scheme. The preclinical programs include CMT1A GABAB PAM, PTSD mGlu7 NAM, MGlu2 NAM, Parkinson disease mGlu4 PAM and Neurodegenerative disorders mGlu3 PAM. PAM is the primary component of GABAB PAM.